We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Drug Industry Daily: Subscribe Now!
Email
Tweet

Drug Industry Daily: Subscribe Now!

Subscribe Now - Single-User

Drug Industry Daily

Compliance — and business success — are rooted in an understanding of the top pharma and regulatory developments that come every single day.

You need to know about and respond to the regulations, guidances and policies coming from the FDA and international regulators; advances in drug research and development; mergers, acquisitions and other deals that change the face of the industry; insights from key opinion leaders; best practices in GMP compliance; and so much more.

You’ll get all of this news and understanding in Drug Industry Daily.

Merged with Drug GMP Report and free daily briefing, Drug Daily Bulletin, the upgraded Drug Industry Daily is all the news you’ve come to rely on with analysis of developing trends and deeper dives into specific areas of concern for drugmakers.

It’s quality you can rely on, as Drug Industry Daily is reported and written by FDAnews’ team of experienced drug industry journalists and subject matter experts.

The content includes columns to keep you apprised of legislative and regulatory developments and FDA-held meetings, as well as timely content from FDAnews management reports and webinars. You can’t afford to go without valuable insights into:

  • Breaking news on COVID-19 (including the launch of new trials; the approvals of vaccines and treatments; and supply deals that the U.S., EC and other governments have struck with drugmakers)
  • Regulatory developments and new regulatory policies by the FDA and other regulatory agency guidances
  • Pharma company mergers, especially when a company is getting into a new therapeutic area
  • Analyses of developments in the pharma industry
  • Developments in drug pricing and drug labeling policies
  • FDA budgets and spending, including approvals and proposals by Congress and the president
  • FDA management and structure
  • Quality and GMP regulatory policies and developments in the industry
  • Patent exclusivity lawsuit rulings and developments
  • FDA inspection policies and schedules
  • FDA enforcement actions
  • Global enforcement trends
  • Pharmacovigilance developments in the EU and elsewhere
  • Recalls

Get ahead — and stay compliant — with the major breaking pharma and regulatory developments and analysis in the upgraded Drug Industry Daily.

Subscribe today.

Start your single-user one-year subscription (250 issues) DID for only $1,695.

Also available: Take advantage of our multi-user and site licenses of Drug Industry Daily, so you’ll have the most-informed workforce! Contact Will Tuttle, Business Development Representative at wtuttle@fdanews.com or +1 612.216.2948 to receive a custom quote.

We’re confident the value DID provides you will pay for itself many times over. If you disagree, there’s our No-Risk, 100% Money-Back Guarantee: If at any time, for any reason, you become dissatisfied with Drug Industry Daily, you may cancel your subscription and receive a full refund. No questions asked.

Upcoming Events

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Consortium Gets EU Funding to Develop Continuous Blood Pressure Monitoring Device

  • FDA Approves GSK’s Oral Drug for Chronic Kidney Disease-Related Anemia

  • Aspivix’s Carevix Cleared to Reduce Pain, Bleeding in Gynecological Procedures

  • FDA Warns That Energy Supplement Contains Active Cialis Ingredient

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing